MedImmune joins research collaboration with the University of California

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF).

The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from university scientists who wish to move their translational research beyond the bench and into product development. The agreement is the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options.  Financial terms around the collaboration were not disclosed.

Call for proposals